The diagnosis of non-small cell lung cancer in the molecular era

Brainard, Jennifer; Farver, Carol

doi:10.1038/s41379-018-0156-x

Cited by 31 publications

(20 citation statements)

References 44 publications

(60 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Lung adenocarcinoma (ADC) is the main subtype of lung cancer [4,5]. In recent years, the diagnosis and treatment methods have been continuously improved, for example, the application of targeted therapy has improved many patients' quality of life [6]. However, the overall survival rate of lung adenocarcinoma is not significantly upgraded [7].…”

Section: Introductionmentioning

confidence: 99%

AHNAK2 Is Associated with Poor Prognosis and Cell Migration in Lung Adenocarcinoma

Zhang

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

Background. Lung adenocarcinoma (LUAD), as the main subtype of lung cancer, is one of the common causes of cancer-related deaths worldwide. The AHNAK family is correlated with cell structure and migration, cardiac calcium channel signaling, and tumor metastasis. Previous studies showed AHNAK2 could promote tumor progression and cell migration in melanoma and renal clear cell carcinoma. However, the role of AHNAK2 in LUAD remains unknown. Methods. We examined the levels of AHNAK2 in pathological specimens and the database of Clinical Proteomic Tumor Analysis Consortium-Lung adenocarcinoma (CPTAC-LUAD), The Cancer Genome Atlas-Lung Adenocarcinoma (TCGA-LUAD), Gene Expression Omnibus dataset (GSE72094, GSE26939), and The Genotype-Tissue Expression (GTEx) of lung tissue samples. Univariate Cox regression, multivariate Cox regression, and Kaplan–Meier survival analysis were performed to reveal the relationship between AHNAK2 and prognosis. A nomogram was constructed to predict 2- or 3-year overall survival and validated via calibration curves, receiver operating characteristic (ROC) analysis, and decision curve analysis (DCA). Furthermore, Gene Ontology (GO) analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis were used to explore the functional role of AHNAK2 in lung adenocarcinoma. Finally, by transfecting siRNA, we examined the regulatory effect of AHNAK2 on cell migration. Results. The expression of AHNAK2 was upregulated in tumor samples and correlated with poor prognosis in LUAD patients. Nomogram with AHNAK2 and clinical parameters showed a good prediction in overall survival (OS), especially the 2-year OS. In addition, functional analyses and wound healing assay suggested that AHNAK2 might be involved in the regulation of migration in LUAD. Conclusion. In summary, our study showed that AHNAK2 might be a novel biomarker in LUAD and revealed the potential mechanism of AHNAK2 in LUAD progression which could provide new insights for target therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

AHNAK2 Is Associated with Poor Prognosis and Cell Migration in Lung Adenocarcinoma

Zhang

et al. 2020

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Lung cancer is the leading cause of cancer-related deaths worldwide (Bray et al, 2018). Non-small cell lung cancer (NSCLC) accounts for about 85% of the lung cancer types, including squamous cell carcinoma, large cell lung cancer, and lung adenocarcinoma (Herbertz et al, 2015;Bray et al, 2018;Brainard and Farver, 2019). Although there are various approaches for its diagnosis and treatments, the 5-year overall survival (OS) rate for patients with advanced lung cancer is less than 15% (Zhou et al, 2011).…”

Section: Lung Cancermentioning

confidence: 99%

Relevance Function of Linc-ROR in the Pathogenesis of Cancer

Chen

Yang

Fang

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) are the key components of non-coding RNAs (ncRNAs) with a length of 200 nucleotides. They are transcribed from the so-called "dark matter" of the genome. Increasing evidence have shown that lncRNAs play an important role in the pathophysiology of human diseases, particularly in the development and progression of tumors. Linc-ROR, as a new intergenic non-protein coding RNA, has been considered to be a pivotal regulatory factor that affects the occurrence and development of human tumors, including breast cancer (BC), colorectal cancer (CRC), pancreatic cancer (PC), hepatocellular carcinoma (HCC), and so on. Dysregulation of Linc-ROR has been closely related to advanced clinicopathological factors predicting a poor prognosis. Because linc-ROR can regulate cell proliferation, apoptosis, migration, and invasion, it can thus be used as a potential biomarker for patients with tumors and has potential clinical significance as a therapeutic target. This article reviewed the role of linc-ROR in the development of tumors, its related molecular mechanisms, and clinical values.

show abstract

“…Ultimately, the aim of harmonization is to ensure a robust and comprehensive final diagnosis through which to direct treatment and achieve optimal outcomes. Therefore, the healthcare service provider requires not only the physical infrastructure, but also the communication networks to facilitate effective collaboration among healthcare professionals involved in providing the comprehensive diagnosis (62). This may require ongoing education to meet the needs of all stakeholders.…”

Section: Challenge 4: Harmonization Of Diagnostics Involves Several Dmentioning

confidence: 99%

Implementation of Novel Molecular Biomarkers for Non-small Cell Lung Cancer in the Netherlands: How to Deal With Increasing Complexity

et al. 2020

View full text Add to dashboard Cite

The diagnostic landscape of non-small cell lung cancer (NSCLC) is changing rapidly with the availability of novel treatments. Despite high-level healthcare in the Netherlands, not all patients with NSCLC are tested with the currently relevant predictive tumor markers that are necessary for optimal decision-making for today's available targeted or immunotherapy. An expert workshop on the molecular diagnosis of NSCLC involving pulmonary oncologists, clinical chemists, pathologists, and clinical scientists in molecular pathology was held in the Netherlands on December 10, 2018. The aims of the workshop were to facilitate cross-disciplinary discussions regarding standards of practice, and address recent developments and associated challenges that impact future practice. This paper presents a summary of the discussions and consensus opinions of the workshop participants on the initial challenges of harmonization of the detection and clinical use of predictive markers of NSCLC. A key theme identified was the need for broader and active participation of all stakeholders involved in molecular diagnostic services for NSCLC, including healthcare professionals across all disciplines, the hospitals and clinics involved in service delivery, healthcare insurers, and industry groups involved in diagnostic and treatment innovations. Such collaboration is essential to integrate different technologies into molecular diagnostics practice, to increase nationwide patient access to novel technologies, and to ensure consensus-preferred biomarkers are tested.

show abstract

The diagnosis of non-small cell lung cancer in the molecular era

Cited by 31 publications

References 44 publications

AHNAK2 Is Associated with Poor Prognosis and Cell Migration in Lung Adenocarcinoma

AHNAK2 Is Associated with Poor Prognosis and Cell Migration in Lung Adenocarcinoma

Relevance Function of Linc-ROR in the Pathogenesis of Cancer

Implementation of Novel Molecular Biomarkers for Non-small Cell Lung Cancer in the Netherlands: How to Deal With Increasing Complexity

Contact Info

Product

Resources

About